Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification.
Guldvik IJ, Zuber V, Braadland PR, Grytli HH, Ramberg H, Lilleby W, Thiede B, Zucknick M, Saatcioglu F, Gislefoss R, Kvåle R, George A, Grönberg H, Wiklund F, Neal DE, Gnanapragasam VJ, Taskén KA, Mills IG. Guldvik IJ, et al. Among authors: saatcioglu f. Eur Urol Open Sci. 2020 Oct 13;21:51-60. doi: 10.1016/j.euros.2020.08.007. eCollection 2020 Oct. Eur Urol Open Sci. 2020. PMID: 34337468 Free PMC article.
The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy.
Lazarevic B, Hammarström C, Yang J, Ramberg H, Diep LM, Karlsen SJ, Kucuk O, Saatcioglu F, Taskèn KA, Svindland A. Lazarevic B, et al. Among authors: saatcioglu f. Br J Nutr. 2012 Dec 28;108(12):2138-47. doi: 10.1017/S0007114512000384. Epub 2012 Mar 8. Br J Nutr. 2012. PMID: 22397815 Clinical Trial.
Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial.
Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, Berg RE, Egge-Jacobsen W, Hammarstrom C, Svindland A, Kucuk O, Saatcioglu F, Taskèn KA, Karlsen SJ. Lazarevic B, et al. Among authors: saatcioglu f. Nutr Cancer. 2011;63(6):889-98. doi: 10.1080/01635581.2011.582221. Epub 2011 Jun 29. Nutr Cancer. 2011. PMID: 21714686 Clinical Trial.
Divergent androgen regulation of unfolded protein response pathways drives prostate cancer.
Sheng X, Arnoldussen YJ, Storm M, Tesikova M, Nenseth HZ, Zhao S, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen H, Mills IG, Jin Y, Hotamisligil G, Saatcioglu F. Sheng X, et al. Among authors: saatcioglu f. EMBO Mol Med. 2015 Jun;7(6):788-801. doi: 10.15252/emmm.201404509. EMBO Mol Med. 2015. PMID: 25864123 Free PMC article.
IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.
Sheng X, Nenseth HZ, Qu S, Kuzu OF, Frahnow T, Simon L, Greene S, Zeng Q, Fazli L, Rennie PS, Mills IG, Danielsen H, Theis F, Patterson JB, Jin Y, Saatcioglu F. Sheng X, et al. Among authors: saatcioglu f. Nat Commun. 2019 Jan 24;10(1):323. doi: 10.1038/s41467-018-08152-3. Nat Commun. 2019. PMID: 30679434 Free PMC article.
Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.
Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG. Urbanucci A, et al. Among authors: saatcioglu f. Cell Rep. 2017 Jun 6;19(10):2045-2059. doi: 10.1016/j.celrep.2017.05.049. Cell Rep. 2017. PMID: 28591577 Free PMC article.
Molecular mechanisms of apoptosis in prostate cancer.
Lorenzo PI, Arnoldussen YJ, Saatcioglu F. Lorenzo PI, et al. Among authors: saatcioglu f. Crit Rev Oncog. 2007 Aug;13(1):1-38. doi: 10.1615/critrevoncog.v13.i1.10. Crit Rev Oncog. 2007. PMID: 17956216 Review.
Dual specificity phosphatases in prostate cancer.
Arnoldussen YJ, Saatcioglu F. Arnoldussen YJ, et al. Among authors: saatcioglu f. Mol Cell Endocrinol. 2009 Oct 15;309(1-2):1-7. doi: 10.1016/j.mce.2009.05.019. Epub 2009 Jun 6. Mol Cell Endocrinol. 2009. PMID: 19501628 Review.
94 results